EX-99.1 2 abbv-20230630nonxgaapxex991.htm EX-99.1

AbbVie Inc.

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

(Unaudited)

 

(in millions, except per share data)			Quarter Ended June 30, 2023																		Full-Year Ended December 31, 2023
			Acquired IPR&D and Milestones Expense						Adjusted Diluted EPS Range												Acquired IPR&D and Milestones Expense						Adjusted Diluted EPS Range
									Low						High												Low						High
Previously announced guidance excluding Q2 2023 acquired IPR&D and milestones expense			$	—					$	2.90					$	3.00					$	150					$	10.72					$	11.12
Q2 2023 acquired IPR&D and milestones expense			280						(0.15)						(0.15)						280						(0.15)						(0.15)
Guidance including Q2 2023 acquired IPR&D and milestones expensea			$	280					$	2.75					$	2.85					$	430					$	10.57					$	10.97

a    The Company's 2023 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2023, as both cannot be reliably forecasted.

    1